This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Government Pot Contract Open for Bids, but Nobody Wants It

Doblin disagrees saying, "It's old, dried, brittle and mixed with seeds and stems. This has not been quality. Their goal is to provide poor quality medical marijuana to researchers in order to get negative results. Some of the marijuana is over 10 years old."

The battle to break the NIDA monopoly has raged for years. As recently as 2013, Dr. Craker has been denied by the United States Court of Appeals the ability to grow cannabis for research, which is especially ironic because in Massachusetts medicinal marijuana is legal and 20 dispensaries have been approved. The Court also felt the monopoly concern wasn't an issue because anyone can bid on the contract when it comes up for renewal. The Court also stated that NIDA gives it test pot either free or at no cost.

However, Doblin said, "We've been working with Israel -- they are able to grow it for 50 cents a gram, Uruguay sets its price at $1 a gram, NIDA's price from years ago was $7. That's not a competitive price."

>> Read More: Medical Marijuana in Canada Set to Boom

NIDA's monopoly shuts out American producers and could end up opening up the market to foreign farmers. Canadian growers are trying to get a drug master file opened at the FDA, but it will take a year to get it accepted. Dobkin said, "The NIDA monopoly is doomed. It will be broken by foreign imports."

NIDA insists that it welcomes other bids but that it hasn't received any in the past.

"Besides the University of Mississippi, the only other proposal ever received was when this was re-competed in 1999," Grabus said. "A commercial organization submitted a proposal which was subsequently determined unacceptable by a peer review committee. Thus, to date, we have never contracted with any other organization to grow, analyze, store and distribute the marijuana."

Maybe when the word gets out that the contract is open for bidding American producers will apply. However, Doblin isn't optimistic. "You have to demonstrate you have an FDA license to apply, which only Ol' Miss has. It's fruitless for anyone else to apply. If you currently cultivate marijuana, then the DEA says you are violating Federal law and therefore you can't get an FDA license."

-- Written by Debra Borchardt in New York.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CBIS $0.05 0.00%
AAPL $129.36 0.21%
FB $79.61 -0.18%
GOOG $573.64 0.40%
TSLA $199.54 1.10%


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs